STATE COLLEGE, Pa., Feb. 8 /PRNewswire/ -- SpectruMedix LLC is pleased to announce the addition of Toronto, Canada-based Transition Technologies Inc. to its growing list of worldwide distributors. The first Reveal(TM) Genetic Analysis Platform was placed in London, Ontario in January 2005. Transition Technologies will be responsible for marketing, sales, installation and service for SpectruMedix products to academic, government and pharmaceutical research companies for the identification and discovery of genetic variation leading to disease and other health-related issues. Reveal(TM) is a non- specific detection method which enables the researcher to rapidly identify novel genetic variation. This method allows sample analysis without prior knowledge of the size or sequence of the DNA amplicon. The Reveal(TM) assay is less labor intensive and has a higher throughput than other commercially available methods.
According to SpectruMedix LLC President and CEO John Ritson, "The selection of Transition Technologies to distribute our products to the Canadian market was a perfect fit. Their existing sales activities and ability to seamlessly integrate our platform and products into their product portfolio is what we were searching for and needed to properly address this market."
Dr. Scott McGeorge, President of Transition Technologies, adds, "The SpectruMedix platform is a natural extension to the DHPLC technology we have been so successful with in Canada to-date. The very high throughput capabilities of the Reveal(TM) system combined with flexible sequencing and powerful genotyping strategies provide a very comprehensive portfolio for our customer base."
Kevin Gutshall, Director of Sales and Business Development, reports, "We have seen a sharp increase in demand for new technology in Canada for DNA variation identification and discovery. Researchers in Canada are asking for accurate, high throughput, multi-function platforms for the identification and discovery of genetic variation."
About SpectruMedix, LLC
SpectruMedix LLC is an innovative manufacturer of high throughput capillary electrophoresis instrumentation for genetic analysis. The company's proprietary technology for on-column detection of DNA and temperature gradient capillary electrophoresis allows SpectruMedix to address an unmet need for high throughput screening for mutations present in DNA samples as well as a number of other genetic analysis applications. Systems are available in 24, 96, 192, and 384 capillary configurations.
More information on the Reveal(TM) System can be obtained from http://www.spectrumedix.com/ .
CONTACT: Kevin Gutshall, Director of Sales and Business Development ofSpectruMedix LLC, +1-814-867-8600, ext. 266